TY - JOUR T1 - <em>Mycoplasma genitalium</em> in Toronto, Ont JF - Canadian Family Physician JO - Can Fam Physician SP - e96 LP - e101 VL - 62 IS - 2 AU - Dionne Gesink AU - C. Sarai Racey AU - Christine Seah AU - Sandra Zittermann AU - Leo Mitterni AU - Jerry Juzkiw AU - Heather Jamieson AU - Jane Greer AU - Sudesh Singh AU - Jørgen Skov Jensen AU - Vanessa Allen Y1 - 2016/02/01 UR - http://www.cfp.ca/content/62/2/e96.abstract N2 - Objective To estimate the prevalence of Mycoplasma genitalium in Toronto, Ont; detect mutations associated with macrolide and fluoroquinolone resistance; and describe treatment outcomes.Design Prospective, cross-sectional study.Setting A sexual health clinic in Toronto.Participants A consecutive sample of men and women attending the sexual health clinic between September 1, 2013, and December 20, 2013.Interventions Participants underwent testing for M genitalium, along with standard sexually transmitted infection screening. All samples that had positive results for M genitalium were tested for mutations associated with resistance to macrolides and fluoroquinolones. Mycoplasma genitalium treatment was based on resistance profile and verified with a test of cure.Main outcome measures Positive results for M genitalium and antibiotic resistance.Results A total of 1193 men and women participated in the study. Overall, 4.5% of the 884 men and 3.2% of the 309 women had positive test results for M genitalium. Asymptomatic infection was common (52.0%). Macrolide resistance–mediating mutations were found in 58.0% of the M genitalium infections. No treatment failure was observed for azithromycin-treated cases. Treatment failure was suspected for 16.7% of cases treated with moxifloxacin.Conclusion Mycoplasma genitalium is present in Canada, with a prevalence comparable to chlamydia and gonorrhea, and has high macrolide and fluoroquinolone resistance. ER -